Scleroderma Peripheral B Lymphocytes Secrete Interleukin‐6 and Transforming Growth Factor β and Activate Fibroblasts

Objective To study the role of B lymphocytes in systemic sclerosis (SSc). Methods Peripheral B cell subpopulations and the production of interleukin‐6 (IL‐6) and transforming growth factor β (TGFβ) were analyzed using flow cytometry and multiplex assay. The fibroblast proliferation rate upon incubat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2017-05, Vol.69 (5), p.1078-1089
Hauptverfasser: Dumoitier, Nicolas, Chaigne, Benjamin, Régent, Alexis, Lofek, Sébastien, Mhibik, Maissa, Dorfmüller, Peter, Terrier, Benjamin, London, Jonathan, Bérezné, Alice, Tamas, Nicolas, Varin‐Blank, Nadine, Mouthon, Luc
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To study the role of B lymphocytes in systemic sclerosis (SSc). Methods Peripheral B cell subpopulations and the production of interleukin‐6 (IL‐6) and transforming growth factor β (TGFβ) were analyzed using flow cytometry and multiplex assay. The fibroblast proliferation rate upon incubation with supernatants from B cells isolated from SSc patients or healthy controls was assessed using XTT, bromodeoxyuridine, and Ki‐67. Collagen production was assessed using a collagen assay. Results Ninety untreated patients (12 males) fulfilling the American College of Rheumatology/European League Against Rheumatism criteria for SSc (23 with diffuse cutaneous SSc [dcSSc] and 67 with limited cutaneous SSc [lcSSc]) and 30 healthy controls were recruited. Increased proportions of B cells expressing CD69 and CD95 were identified among the patients with SSc. B lymphocytes from dcSSc patients versus lcSSc patients and healthy controls expressed increased proportion of cells positive for CD5 (mean ± SD 24.12 ± 7.93% versus 14.09 ± 6.58% [P = 0.03] and 14.21 ± 5.34% [P = 0.01]), CD86 (39.89 ± 22.11% versus 17.72 ± 13.98% [P = 0.0007] and 11.68 ± 11.09% [P 
ISSN:2326-5191
2326-5205
2326-5205
2326-5191
DOI:10.1002/art.40016